pharmaphorum January 21, 2025
People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer’s, but an increase in some other conditions like kidney stones, low blood pressure, arthritis and joint pain, and pancreatitis.
Those are the findings of an observational study that claims to be the largest ever conducted on the drug class – based on 2.4 million people in the US Department of Veterans Affairs health record databases, including a cohort of 215,000 treated with GLP-1RAs – and has been published in the journal Nature Medicine.
It compared health outcomes among patients taking GLP-1RAs like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide for diabetes and obesity to ‘usual care’ – in...
Today's Sponsors
Today's Sponsor